Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Mitarbeiter des Rudolf-Boehm-Institutes
Module III – CAS in Radiopharmaceutical Chemistry/Radiopharmacy | ETH Zurich
Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model
Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells
MedTech-2022 Conferences | MedTech -2022 | MedTech 2022 Events | Pharma Industry and MedTech | MedTech Conferences | MedTech Meetings | Pharma Industry and MedTech | | Pharma Industry and MedTech Congress
Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo
Mitarbeiter des Rudolf-Boehm-Institutes
Mitarbeiter des Rudolf-Boehm-Institutes
Analysis of SATB1 in Head and Neck Squamous Cell Carcinoma
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Leipziger Pharmakologen forschen an Molekülen gegen Prostatakrebs
Mitarbeiter des Rudolf-Boehm-Institutes
Let Life Sciences meet you Let Life Sciences meet you
Perspectives, issues and solutions in RNAi therapy: the expected and the less expected
Tyrosine-Modification of Polypropylenimine (PPI) and Polyethylenimine (PEI) Strongly Improves Efficacy of siRNA-Mediated Gene Kn
PDF) The proto-oncogene Pim-1 is a target of miR-33a | Marshall Thomas - Academia.edu
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology